These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37548462)

  • 1. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.
    Dey S; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Aug; ():. PubMed ID: 37548462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
    Freeman MW; Halvorsen YD; Marshall W; Pater M; Isaacsohn J; Pearce C; Murphy B; Alp N; Srivastava A; Bhatt DL; Brown MJ;
    N Engl J Med; 2023 Feb; 388(5):395-405. PubMed ID: 36342143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New trials in resistant hypertension: mixed blessing stories.
    Zoccali C; Mallamaci F; De Nicola L; Minutolo R
    Clin Kidney J; 2024 Jan; 17(1):sfad251. PubMed ID: 38186891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Am J Cardiovasc Drugs; 2023 May; 23(3):277-286. PubMed ID: 36790596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease.
    Awosika A; Khan A; Adabanya U; Omole AE; Millis RM
    Cureus; 2023 Mar; 15(3):e36184. PubMed ID: 36937127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function.
    Freeman MW; Halvorsen YD; Bond M; Murphy B; Isaacsohn J
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):410-418. PubMed ID: 38311833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.
    Feldman JM; Frishman WH; Aronow WS
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38358268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone synthase inhibitor "Baxdrostat" for resistant hypertension: A clinical approach or futuristic idea?
    Siddiqui MO; Qureshi AA; Siddiqui A; Ain NU
    Chronic Dis Transl Med; 2024 Jun; 10(2):146-148. PubMed ID: 38872758
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone for hypertension.
    Tam TS; Wu MH; Masson SC; Tsang MP; Stabler SN; Kinkade A; Tung A; Tejani AM
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD008996. PubMed ID: 28245343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aldosterone blockade in essential hypertension].
    Venco A; Grandi AM
    Ital Heart J; 2005 May; 6 Suppl 1():34S-42S. PubMed ID: 15945298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.
    Dudenbostel T; Calhoun DA
    Am J Hypertens; 2017 Feb; 30(2):103-109. PubMed ID: 27609503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Lawrence KA; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007066. PubMed ID: 28379619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.